Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T22:20:49.932Z.
Consensus retrieved: 2026-10-06T09:07:07.660Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:20:49.932Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c84a17f2c5c981e3cafbb97a54cdccede593a8f239875ee545639e7176ba2e68
Forward PE Ratio (N/A) = Dated Quote Price ($9.75) / Consensus Forward EPS ($-0.69)
FORWARD PE RATIO
N/A
Atara Biotherapeutics, Inc.
Market Cap
$87.85M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | $87.85M | N/A |
| CareCloud, Inc. (CCLD)vs › | $87.96M | 7.53 |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $87.27M | N/A |
| electroCore, Inc. (ECOR)vs › | $89.44M | N/A |
| Equillium, Inc. (EQ)vs › | $89.78M | N/A |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $85.86M | N/A |
| ImmuCell Corporation (ICCC)vs › | $90.20M | N/A |
| Biomea Fusion, Inc. (BMEA)vs › | $90.37M | N/A |
| Rallybio Corporation (RLYB)vs › | $90.64M | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.13M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $9.75, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.69 | $-1.98 – $0.63 | 2 | n/m |
| 2027-12-31 | $0.94 | $0.14 – $1.75 | 2 | 10.4x |
| 2028-12-31 | $0.44 | $-1.10 – $3.08 | 3 | 22.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
